Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 17/20 | 0.68 |
| ▸ | DBF4 | Q9UBU7 | 17/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336462 | 0.91 | CDC7 (0.61) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL15049083 | 0.90 | TRPM8 (0.60) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL15048987 | 0.89 | TRPM8 (0.63) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL15049133 | 0.88 | TRPM8 (0.61) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL5234021 | 0.88 | CDC7 (0.67) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL27942950 | 0.86 | CDC7 (0.65) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL31318864 | 0.85 | CDC7 (0.54) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL6226185 | 0.85 | CDC7 (0.53) | CDC7DBF4KDM4EMEN1KMT2A | |
| SCHEMBL17317811 | 0.83 | CDC7 (0.47) | CDC7DBF4KDM4EMEN1HSP90AA1 | |
| SCHEMBL15049533 | 0.83 | TRPM8 (0.66) | CDC7DBF4KDM4EMEN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | CDC7 893/4885DBF4 4312/4885KDM4E 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.